Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06941857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started2025-09-04
View on ClinicalTrials.gov ↗

Amendment history

2026-04-30
Study Status v7
Primary completion date2030-09→2028-12
Completion date2030-09→2028-12
2025-12-01
Study Status, Contacts/Locations v6
Study sitescontacts updated at 1 of 1 site
2025-09-04
Study Status v5
Primary completion date2030-07→2030-09
Completion date2030-07→2030-09
Start dateestimated 2025-09→confirmed 2025-09-04
2025-08-27
Study Status v4
Start date2025-08→2025-09
2025-08-01
Study Status v3
Start date2025-07→2025-08
Show 2 earlier versions
2025-07-16
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2025-06-23
Study Status v1
Primary completion date2030-06→2030-07
Completion date2030-06→2030-07
Start date2025-06→2025-07
2025-04-16
Original filing
The purpose of this study is to evaluate safety of the treatment regimen and identify any novel toxicities.
Trial Details
NCT Number NCT06941857
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: NextCure, Inc., Lustgarten Foundation
Conditions Pancreatic Cancer
Enrollment 20 participants
Start Date 2025-09-04
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-05